Maintenance — holding the cut without the deficit

The cut is over. The deficit is closed. And this is exactly when most people give back 40-60% of the loss inside six months — not because they "fell off," but because shrinking fat cells trigger a hardcoded biological rebound that runs on a different gene set than fat loss itself.

The research describes a specific mechanism here. When fat cells shrink, mechanical stress damages the cell membrane. Heat shock proteins — particularly HSP60 — get produced to repair the damage, and HSP60 happens to be one of the strongest inflammatory signaling molecules in adipose tissue. The signal it sends to the body, in plain biology: refill these cells. The maintenance phase doesn't run on the same genes as the cut. Entirely different gene expression patterns activate post-fat-loss, and those genes are biased toward regain.

That is the substrate-cited reason most cuts fail at the maintenance phase, not at the deficit phase. The body isn't trying to maintain. It's trying to refill. Your protocol for the next 12+ months has to actively oppose that signaling — not just with calories, but with a compound stack that keeps AMPK signaling active, insulin sensitivity high, and GH pulsatility intact at far lower doses than the cut required.

What the maintenance physiology actually demands

Three things have to stay solved indefinitely.

Mitochondrial signaling. During the cut you ran MOTS-c hard — typically 5-10 mg, 3-5x/week — to keep AMPK activated, fat oxidation high, and insulin sensitivity protective against the deficit. After the cut, AMPK activity is exactly what prevents fat cells from refilling with the energy you're now adding back in. The substrate is explicit: MOTS-c works as an "exercise mimetic," triggering the same metabolic cascades as vigorous training — fatty acid oxidation, glucose uptake, metabolic flexibility. Lose this signal and you lose the cut.

NAD+ economics. NMN raises NAD+ supply. 5-Amino-1MQ blocks NNMT, which decreases NAD+ waste. The net-positive NAD+ balance fuels sirtuin activity, which keeps the mitochondrial gene set that favors lean mass active over the storage-favoring set. The substrate flags this as the reason both compounds run together rather than either alone — neither achieves the same balance solo.

GH pulsatility without insulin antagonism. CJC-1295 + Ipamorelin restored your sleep-time GH surge and protected lean mass during the deficit. The maintenance problem: GH naturally antagonizes insulin. The substrate is direct — if fasting insulin climbs above 8 uIU/mL at maintenance, GH secretagogues can actively worsen insulin resistance and re-create the metabolic state you just spent 16 weeks reversing. The maintenance dose schedule has to be lower, more pulsatile, and gated against rising fasting insulin.

The fourth piece — and the substrate-cited reason high-volume peptide practices keep certain compounds running indefinitely — is that some peptides have such fundamental signaling roles and such clean safety profiles that they belong in a "forever stack." MOTS-c at cycled microdose is one. BPC-157 at microdose is another. The cycling math changes from "on/off to prevent receptor downregulation" to "low-dose continuous to maintain a pathway you can't easily replicate any other way."

The maintenance stack

Notably absent: anything aggressive on the GH axis (no Tesamorelin, no MK-677), nothing on the GLP-1 axis (Semaglutide / Tirzepatide / Retatrutide are cut tools, not maintenance tools), no AOD-9604. Maintenance physiology doesn't tolerate the same signaling intensity the cut required.

What you should feel

The substrate-described maintenance experience, week-by-week:

• Weeks 1-2 post-cut. Hunger signaling normalizes as leptin rebounds with the calorie restoration. This is the highest-risk regain window — the body is reading the refeed as the signal to refill fat cells. The MOTS-c + 5-Amino-1MQ pairing is doing the heaviest work here, holding AMPK active against the rising energy availability.
• Weeks 3-6. Body composition stabilizes. The substrate describes a reverse-diet rhythm — calories climb slowly while body weight holds within 1-2 kg of the cut endpoint. Strength climbs back to pre-cut output. Sleep quality from the nighttime Ipamorelin pulse drives most of the visible recomposition in this window.
• Weeks 7-12. True maintenance state. Energy is high, training output is high, fasting glucose sits in the 80s, fasting insulin holds under 8 uIU/mL. This is the metabolic state you defended.
• Months 4-12. The re-cut window opens. Practitioner consensus is that a second cut can be initiated after 12-16 weeks of stable maintenance — not sooner. Running consecutive cuts without a maintenance phase between them is the substrate-cited fastest path to metabolic adaptation and a stalled response.

What's NOT happening yet

• The cut isn't "locked in" at week 4. The HSP60-driven regain signal runs for months. Twelve weeks is the minimum maintenance window before the body's defended-weight setpoint shifts down.
• You're not done with labs. Fasting insulin, fasting glucose, IGF-1, fT3, and lipid panel get rechecked at week 6 and week 12 of maintenance. The substrate is direct: GH secretagogue protocols are gated against fasting insulin, and a drift above 8 uIU/mL means you pull back the CJC + Ipa stack before it makes regain easier.
• You can't push new lean mass on this stack. The maintenance stack defends the cut. It doesn't drive growth. If a recomposition push is the next goal, that's a different protocol with different compounds, and it starts only after the maintenance window closes.
• The lifestyle layer isn't optional. Zone 2 training (3-4x/week, 30-45 min) and resistance training at ≥ 30% 1RM are the substrate-described non-pharmacological levers that upregulate glucose transporters and improve insulin sensitivity directly. The peptide stack amplifies these. It does not replace them.

Research describes this pattern. Track your fasting insulin, hold the calorie band, and re-protocol when the data — not the calendar — tells you to.